SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report issued on Monday, Benzinga reports. Chardan Capital currently has a $25.00 price objective on the stock.

Several other research firms have also recently weighed in on SABS. HC Wainwright reaffirmed a buy rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, August 12th. Brookline Capital Management initiated coverage on shares of SAB Biotherapeutics in a research note on Friday, June 7th. They set a buy rating and a $8.00 price target for the company. Finally, Oppenheimer started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, August 28th. They issued an outperform rating and a $12.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and an average price target of $12.75.

SAB Biotherapeutics Stock Up 1.8 %

SABS stock opened at $2.80 on Monday. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.07. The business’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $3.54. SAB Biotherapeutics has a 1-year low of $2.16 and a 1-year high of $10.50.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.34. The company had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. On average, research analysts expect that SAB Biotherapeutics will post -3.59 earnings per share for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SABS. First PREMIER Bank bought a new position in shares of SAB Biotherapeutics during the second quarter worth approximately $60,000. Commodore Capital LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth approximately $1,259,000. BVF Inc. IL bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $6,310,000. Finally, RTW Investments LP bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $6,310,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.